291 related articles for article (PubMed ID: 25979753)
1. EGFR and NF-κB: partners in cancer.
Shostak K; Chariot A
Trends Mol Med; 2015 Jun; 21(6):385-93. PubMed ID: 25979753
[TBL] [Abstract][Full Text] [Related]
2. Co-targeting EGFR and IKKβ/NF-κB signalling pathways in head and neck squamous cell carcinoma: a potential novel therapy for head and neck squamous cell cancer.
Li Z; Liao J; Yang Z; Choi EY; Lapidus RG; Liu X; Cullen KJ; Dan H
Br J Cancer; 2019 Feb; 120(3):306-316. PubMed ID: 30585254
[TBL] [Abstract][Full Text] [Related]
3. Contribution of EGFR and ErbB-3 Heterodimerization to the EGFR Mutation-Induced Gefitinib- and Erlotinib-Resistance in Non-Small-Cell Lung Carcinoma Treatments.
Wang DD; Ma L; Wong MP; Lee VH; Yan H
PLoS One; 2015; 10(5):e0128360. PubMed ID: 25993617
[TBL] [Abstract][Full Text] [Related]
4. First Bispecific Inhibitors of the Epidermal Growth Factor Receptor Kinase and the NF-κB Activity As Novel Anticancer Agents.
Hamed MM; Darwish SS; Herrmann J; Abadi AH; Engel M
J Med Chem; 2017 Apr; 60(7):2853-2868. PubMed ID: 28291344
[TBL] [Abstract][Full Text] [Related]
5. FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR.
Bivona TG; Hieronymus H; Parker J; Chang K; Taron M; Rosell R; Moonsamy P; Dahlman K; Miller VA; Costa C; Hannon G; Sawyers CL
Nature; 2011 Mar; 471(7339):523-6. PubMed ID: 21430781
[TBL] [Abstract][Full Text] [Related]
6. NF-κB activation is an early event of changes in gene regulation for acquiring drug resistance in human adenocarcinoma PC-9 cells.
Fukuoka M; Yoshioka K; Hohjoh H
PLoS One; 2018; 13(8):e0201796. PubMed ID: 30075033
[TBL] [Abstract][Full Text] [Related]
7. Genistein enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitors and inhibits nuclear factor kappa B in nonsmall cell lung cancer cell lines.
Gadgeel SM; Ali S; Philip PA; Wozniak A; Sarkar FH
Cancer; 2009 May; 115(10):2165-76. PubMed ID: 19288574
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of resistance to EGFR tyrosine kinase inhibitors gefitinib/erlotinib and to ALK inhibitor crizotinib.
Tartarone A; Lazzari C; Lerose R; Conteduca V; Improta G; Zupa A; Bulotta A; Aieta M; Gregorc V
Lung Cancer; 2013 Sep; 81(3):328-336. PubMed ID: 23809060
[TBL] [Abstract][Full Text] [Related]
9. Differential Effects of Tyrosine Kinase Inhibitors on Normal and Oncogenic EGFR Signaling and Downstream Effectors.
Kim Y; Apetri M; Luo B; Settleman JE; Anderson KS
Mol Cancer Res; 2015 Apr; 13(4):765-74. PubMed ID: 25573954
[TBL] [Abstract][Full Text] [Related]
10. EGF receptor uses SOS1 to drive constitutive activation of NFκB in cancer cells.
De S; Dermawan JK; Stark GR
Proc Natl Acad Sci U S A; 2014 Aug; 111(32):11721-6. PubMed ID: 25071181
[TBL] [Abstract][Full Text] [Related]
11. A positive feedback loop involving EGFR/Akt/mTORC1 and IKK/NF-kB regulates head and neck squamous cell carcinoma proliferation.
Li Z; Yang Z; Passaniti A; Lapidus RG; Liu X; Cullen KJ; Dan HC
Oncotarget; 2016 May; 7(22):31892-906. PubMed ID: 26895469
[TBL] [Abstract][Full Text] [Related]
12. NF-κB-driven suppression of FOXO3a contributes to EGFR mutation-independent gefitinib resistance.
Chiu CF; Chang YW; Kuo KT; Shen YS; Liu CY; Yu YH; Cheng CC; Lee KY; Chen FC; Hsu MK; Kuo TC; Ma JT; Su JL
Proc Natl Acad Sci U S A; 2016 May; 113(18):E2526-35. PubMed ID: 27091996
[TBL] [Abstract][Full Text] [Related]
13. Liver X receptors agonist GW3965 re-sensitizes gefitinib-resistant human non-small cell lung cancer cell to gefitinib treatment by inhibiting NF-κB in vitro.
Hu Y; Zang J; Cao H; Wu Y; Yan D; Qin X; Zhou L; Fan F; Ni J; Xu X; Sha H; Liu S; Yu S; Wang Z; Ma R; Wu J; Feng J
Oncotarget; 2017 Feb; 8(9):15802-15814. PubMed ID: 28178657
[TBL] [Abstract][Full Text] [Related]
14. NF-κB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancer.
Blakely CM; Pazarentzos E; Olivas V; Asthana S; Yan JJ; Tan I; Hrustanovic G; Chan E; Lin L; Neel DS; Newton W; Bobb KL; Fouts TR; Meshulam J; Gubens MA; Jablons DM; Johnson JR; Bandyopadhyay S; Krogan NJ; Bivona TG
Cell Rep; 2015 Apr; 11(1):98-110. PubMed ID: 25843712
[TBL] [Abstract][Full Text] [Related]
15. Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib.
Servidei T; Riccardi A; Mozzetti S; Ferlini C; Riccardi R
Int J Cancer; 2008 Dec; 123(12):2939-49. PubMed ID: 18803287
[TBL] [Abstract][Full Text] [Related]
16. Prediction of sensitivity to gefitinib/erlotinib for EGFR mutations in NSCLC based on structural interaction fingerprints and multilinear principal component analysis.
Zou B; Lee VHF; Yan H
BMC Bioinformatics; 2018 Mar; 19(1):88. PubMed ID: 29514601
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological synergism of 2,2-dichloroacetophenone and EGFR-TKi to overcome TKi-induced resistance in NSCLC cells.
Yang Z; Hu X; Zhang S; Zhang W; Tam KY
Eur J Pharmacol; 2017 Nov; 815():80-87. PubMed ID: 28870456
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of resistance to ErbB-targeted cancer therapeutics.
Wang Q; Greene MI
J Clin Invest; 2008 Jul; 118(7):2389-92. PubMed ID: 18568082
[TBL] [Abstract][Full Text] [Related]
19. EGFR tyrosine kinases inhibitors in cancer treatment: in vitro and in vivo evidence.
Quatrale AE; Porcelli L; Silvestris N; Colucci G; Angelo A; Azzariti A
Front Biosci (Landmark Ed); 2011 Jan; 16(5):1962-72. PubMed ID: 21196276
[TBL] [Abstract][Full Text] [Related]
20. Understanding resistance to EGFR inhibitors-impact on future treatment strategies.
Wheeler DL; Dunn EF; Harari PM
Nat Rev Clin Oncol; 2010 Sep; 7(9):493-507. PubMed ID: 20551942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
